PEAQX

• CAT Number: I003605
• CAS Number: 459836-30-7
• Molecular Formula: C17H17BrN3O5P
• Molecular Weight: 454.21
• Purity: ≥95%
• Synonyms: [(S)-[[(1S)-1-(4-bromophenyl)ethyl]amino]-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid
• Target: NMDA
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 270 nM(hNMDA A1/A2) [1]
• IUPAC Name: [[[(1S)-1-(4-bromophenyl)ethyl]amino]-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid
• InChI: InChI=1S/C17H17BrN3O5P/c1-9(10-5-7-11(18)8-6-10)19-17(27(24,25)26)12-3-2-4-13-14(12)21-16(23)15(22)20-13/h2-9,17,19H,1H3,(H,20,22)(H,21,23)(H2,24,25,26)/t9-,17?/m0/s1
• InChIKey: XXZGNAZRWCBSBK-WFVOFKTRSA-N
• SMILES: C[C@@H](C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)NC(=O)C(=O)N3)P(=O)(O)O

PEAQX (CAT: I003605) is a potent and orally active NMDA receptor antagonist with a 15-fold selectivity for NMDA receptors containing the NR1A/NR2A subunit combination over those with NR2B subunits. By selectively inhibiting these receptor subtypes, PEAQX modulates excitatory neurotransmission, making it a valuable tool in neuropharmacology research. Its specificity enables the study of NR2A-mediated pathways involved in synaptic plasticity, learning, and memory, as well as their role in neurological disorders such as stroke, epilepsy, and neurodegenerative diseases. PEAQX provides critical insights into NMDA receptor subunit functionality and supports the development of targeted therapeutic agents.